Stockchase Opinions

The Panic-Proof Portfolio (Stockchase Research) Centene CNC-N PAST TOP PICK Apr 11, 2024

(A Top Pick Feb 29/24, Down 7.9%)Stockchase Research Editor: Michael O'Reilly

Our PAST TOP PICK with CNC has triggered its stop at $72.  To remain disciplined, we recommend covering the position at this time.  This will result in a net investment loss of 5%, when combined with our previous recommendation.

$71.680

Stock price when the opinion was issued

Healthcare
It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.

You might be interested:

BUY
His favourite health insurer. CNC mostly manages government health plans, so it will benefit huge from any expansion of medicare. It down modestly from its high, but this boasts an ultra-low 14x earnings. Meanwhile, their acquisitions are working well and they're buying back lots of shares.
BUY
Friday it holds its analysts meeting where he expects to hear of strong cash flow and buybacks. T
BUY
They report Tuesday. It can go higher. It's a takeover target.
BUY

About as cheap as it's been in the last 5 years at 1.25x book. FMV is 93% above current price. Earnings and FMV continue to rise. A good buying opportunity.

premium

This is a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

TOP PICK
Stockchase Research Editor: Michael O'Reilly

CNC provides healthcare to under-insured families and military personnel in the US.  Healthcare is a sector expected to grow for years to come as the population ages.  It trades at 1.6x book and 17x earnings.  Cash reserves are growing as stock is aggressively bought back and debt is retired.  We recommend placing a stop-loss at $63, looking to achieve $88 -- upside potential of 20%.  Yield 0% 

(Analysts’ price target is $88.33)
premium

This is a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

TOP PICK
Stockchase Research Editor: Michael O’Reilly

We reiterate CNC, a provider of healthcare to under-insured families and military personnel in the US as a TOP PICK.  It continues to build cash reserves, while retiring debt and buying back shares.  It trades at 16x earnings, under 2x book and supports a 10% ROE.  We recommend trailing up the stop (from $63) to $72, looking to achieve $90 — upside potential of 16%.  Yield 0%

(Analysts’ price target is $89.64)
WATCH

Support level has definitely been broken. Lower lows, lower highs. All that is negative technically. Looking at a 3-year chart, now testing support from 2023. If that can hold, it's not so bad a picture.